Bentley Cheatham

Bentley Cheatham currently serves as Vice President at Vogenx, Inc., a position held since 2022. Previously, Bentley held similar leadership roles as Vice President at Avolynt, Inc. from 2016 to 2021 and as CEO of BHV Pharma from 2013 to March 2016. Prior experience includes serving as Vice President of R&D at Zen-Bio from 2009 to 2014, Director of Biology at Ribonomics from 2002 to February 2009, and Director of Cell Therapy at Artecel Sciences in 2001-2002. Academic involvement includes roles as Assistant Professor and Investigator at Harvard Medical School and Joslin Diabetes Center from 1996 to 2001 and Instructor during a post-doctoral fellowship from 1989 to 1996. Bentley earned a PhD in Biochemistry from the University of Tennessee, Knoxville, and completed post-doctoral studies at Harvard Medical School from 1989-1993.